ACG Case Reports Journal
Cure8 research brief
Why This Matters
This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.
It suggests dual-targeted biologic/small-molecule therapy may be an option when other treatments fail, but evidence is from a single case.
Who Should Pay Attention
Adolescents and parents/caregivers facing refractory perianal Crohn’s disease, gastroenterologists and pediatric IBD specialists, clinicians considering combination therapy for severe perianal complications.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Case report (abstract) describing a 17-year-old girl with severe, refractory perianal Crohn’s disease (including rectovaginal fistula) who flared on upadacitinib monotherapy with MRI-confirmed perianal abscesses.
Addition of ustekinumab to upadacitinib led to marked clinical improvement and radiographic resolution on follow-up MRI; no adverse events were reported. Structured content depth: abstract — this brief is grounded in the article abstract provided by the journal.
Keep In Mind
This is a single-case report presented as an abstract. Case reports cannot establish safety or efficacy; they may generate hypotheses that require controlled studies. Details such as dosing, prior therapies, and longer-term outcomes are not available in the abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACG Case Reports Journal
AuthorsSathe Neha, Meredith Kline, Amelia Kellar +2 more
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Ustekinumab combined with upadacitinib promotes endoscopic healing in moderate-to-severe Crohn's disease with anti-TNF-α failure.
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...